Cancer Reviews -- Update 2008/7

Emerging Roles of DMP1 in Lung Cancer

Kazushi Inoue
, Takayuki Sugiyama
, Pankaj Taneja
, Rachel L. Morgan
, and Donna P. Frazier

Cancer Res. 2008 68: 4487-4490. doi: 10.1158/0008-5472.CAN-07-6791 [Abstract] [Full Text] [PDF]

Caspase-8: Fly or Die

Steven M. Frisch

Cancer Res. 2008 68: 4491-4493. doi: 10.1158/0008-5472.CAN-08-0952 [Abstract] [Full Text] [PDF]

Zinc ${alpha}$ 2-Glycoprotein: A Multidisciplinary Protein

Md. Imtaiyaz Hassan
, Abdul Waheed
, Savita Yadav
, Tej P. Singh
, and Faizan Ahmad

Mol. Cancer Res. 2008 6: 892-906. doi: 10.1158/1541-7786.MCR-07-2195 [Abstract] [Full Text] [PDF]

Is Tumor Growth Sustained by Rare Cancer Stem Cells or Dominant Clones?

Jerry M. Adams
and Andreas Strasser

Cancer Res. 2008 68: 4018-4021. doi: 10.1158/0008-5472.CAN-07-6334 [Abstract] [Full Text] [PDF]

Crucial Role of Interleukin-4 in the Survival of Colon Cancer Stem Cells

Maria Giovanna Francipane
, Mileidys Perez Alea
, Ylenia Lombardo
, Matilde Todaro
, J.P. Medema
, and Giorgio Stassi

Cancer Res. 2008 68: 4022-4025. doi: 10.1158/0008-5472.CAN-07-6874 [Abstract] [Full Text] [PDF]

Emerging Roles of DMP1 in Lung Cancer

Kazushi Inoue
, Takayuki Sugiyama
, Pankaj Taneja
, Rachel L. Morgan
, and Donna P. Frazier

Cancer Res. 2008 68: 4487-4490. doi: 10.1158/0008-5472.CAN-07-6791 [Abstract] [Full Text] [PDF]

Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies

Lionel Apetoh
, Antoine Tesniere
, François Ghiringhelli
, Guido Kroemer
, and Laurence Zitvogel

Cancer Res. 2008 68: 4026-4030. doi: 10.1158/0008-5472.CAN-08-0427 [Abstract] [Full Text] [PDF]

Systems-Level Analysis of ErbB4 Signaling in Breast Cancer: A Laboratory to Clinical Perspective

Chih-Pin Chuu
, Rou-Yu Chen
, John L. Barkinge
, Mark F. Ciaccio
, and Richard B. Jones

Mol. Cancer Res. 2008 6: 885-891. doi: 10.1158/1541-7786.MCR-07-0369 [Abstract] [Full Text] [PDF]

Zinc ${alpha}$ 2-Glycoprotein: A Multidisciplinary Protein

Md. Imtaiyaz Hassan
, Abdul Waheed
, Savita Yadav
, Tej P. Singh
, and Faizan Ahmad

Mol. Cancer Res. 2008 6: 892-906. doi: 10.1158/1541-7786.MCR-07-2195 [Abstract] [Full Text] [PDF]

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

Jorge A. Garcia
and David Danielpour

Mol. Cancer Ther. 2008 7: 1347-1354. doi: 10.1158/1535-7163.MCT-07-2408 [Abstract] [Full Text] [PDF]

Unraveling the Mystery of Erythropoietin-Stimulating Agents in Cancer Promotion

Kelly A. May
and Fadlo R. Khuri

Cancer Res. 2008 68: 4013-4017. doi: 10.1158/0008-5472.CAN-07-3324 [Abstract] [Full Text] [PDF]

Molecular Interactions between Dying Tumor Cells and the Innate Immune System Determine the Efficacy of Conventional Anticancer Therapies

Lionel Apetoh
, Antoine Tesniere
, François Ghiringhelli
, Guido Kroemer
, and Laurence Zitvogel

Cancer Res. 2008 68: 4026-4030. doi: 10.1158/0008-5472.CAN-08-0427 [Abstract] [Full Text] [PDF]

Crucial Role of Interleukin-4 in the Survival of Colon Cancer Stem Cells

Maria Giovanna Francipane
, Mileidys Perez Alea
, Ylenia Lombardo
, Matilde Todaro
, J.P. Medema
, and Giorgio Stassi

Cancer Res. 2008 68: 4022-4025. doi: 10.1158/0008-5472.CAN-07-6874 [Abstract] [Full Text] [PDF]

Oncologic Phase 0 Trials Incorporating Clinical Pharmacodynamics: from Concept to Patient

James H. Doroshow
and Ralph E. Parchment

Clin. Cancer Res. 2008 14: 3658-3663. doi: 10.1158/1078-0432.CCR-07-4562 [Abstract] [Full Text] [PDF]

The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials

A. Hilary Calvert
and Ruth Plummer

Clin. Cancer Res. 2008 14: 3664-3669. doi: 10.1158/1078-0432.CCR-07-4559 [Abstract] [Full Text] [PDF]

Leveraging Exploratory Investigational New Drug Studies to Accelerate Drug Development

David Jacobson-Kram
and George Mills

Clin. Cancer Res. 2008 14: 3670-3674. doi: 10.1158/1078-0432.CCR-07-4558 [Abstract] [Full Text] [PDF]

Designing Phase 0 Cancer Clinical Trials

Anthony J. Murgo
, Shivaani Kummar
, Larry Rubinstein
, Martin Gutierrez
, Jerry Collins
, Robert Kinders
, Ralph E. Parchment
, Jiuping Ji
, Seth M. Steinberg
, Sherry X. Yang
, Melinda Hollingshead
, Alice Chen
, Lee Helman
, Robert Wiltrout
, Joseph E. Tomaszewski
, and James H. Doroshow

Clin. Cancer Res. 2008 14: 3675-3682. doi: 10.1158/1078-0432.CCR-07-4560 [Abstract] [Full Text] [PDF]

Phase 0 Trials: An Industry Perspective

Helen Eliopoulos
, Vincent Giranda
, Robert Carr
, Rita Tiehen
, Terri Leahy
, and Gary Gordon

Clin. Cancer Res. 2008 14: 3683-3688. doi: 10.1158/1078-0432.CCR-07-4586 [Abstract] [Full Text] [PDF]

Patient Perspectives on Phase 0 Clinical Trials

Martin Gutierrez
and Deborah Collyar

Clin. Cancer Res. 2008 14: 3689-3691. doi: 10.1158/1078-0432.CCR-07-4561 [Full Text] [PDF]

The Ethics of Phase 0 Oncology Trials

Emily Abdoler
, Holly Taylor
, and David Wendler

Clin. Cancer Res. 2008 14: 3692-3697. doi: 10.1158/1078-0432.CCR-08-0876 [Abstract] [Full Text] [PDF]

Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions

Sabina Signoretti
, Gennady Bratslavsky
, Frederick M. Waldman
, Victor E. Reuter
, John Haaga
, Maria Merino
, George V. Thomas
, Michael R. Pins
, Towia Libermann
, John Gillespie
, Joseph E. Tomaszewski
, Carolyn C. Compton
, Andrew Hruszkewycz
, W. Marston Linehan
, and Michael B. Atkins

Clin. Cancer Res. 2008 14: 3699-3705. doi: 10.1158/1078-0432.CCR-07-4733 [Abstract] [Full Text] [PDF]